These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 21938512)

  • 1. Alkaptonuria: treasure your exceptions.
    Cox TM
    J Inherit Metab Dis; 2011 Dec; 34(6):1113-4. PubMed ID: 21938512
    [No Abstract]   [Full Text] [Related]  

  • 2. NTBC and alkaptonuria.
    Anikster Y; Nyhan WL; Gahl WA
    Am J Hum Genet; 1998 Sep; 63(3):920-1. PubMed ID: 9718357
    [No Abstract]   [Full Text] [Related]  

  • 3. Alkaptonuria.
    Lorenzini S; Mannoni A; Selvi E
    N Engl J Med; 2003 Apr; 348(14):1408; author reply 1408. PubMed ID: 12672874
    [No Abstract]   [Full Text] [Related]  

  • 4. A novel therapeutic trial of homogentisic aciduria in a murine model of alkaptonuria.
    Suzuki Y; Oda K; Yoshikawa Y; Maeda Y; Suzuki T
    J Hum Genet; 1999; 44(2):79-84. PubMed ID: 10083729
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The role of nitisinone in tyrosine pathway disorders.
    Lock E; Ranganath LR; Timmis O
    Curr Rheumatol Rep; 2014 Nov; 16(11):457. PubMed ID: 25266991
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Suitability of nitisinone for alkaptonuria.
    Häberle J
    Lancet Diabetes Endocrinol; 2020 Sep; 8(9):732-733. PubMed ID: 32822593
    [No Abstract]   [Full Text] [Related]  

  • 7. A 3-year randomized therapeutic trial of nitisinone in alkaptonuria.
    Introne WJ; Perry MB; Troendle J; Tsilou E; Kayser MA; Suwannarat P; O'Brien KE; Bryant J; Sachdev V; Reynolds JC; Moylan E; Bernardini I; Gahl WA
    Mol Genet Metab; 2011 Aug; 103(4):307-14. PubMed ID: 21620748
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Alkaptonuria - Many questions answered, further challenges beckon.
    Davison AS; Hughes AT; Milan AM; Sireau N; Gallagher JA; Ranganath LR
    Ann Clin Biochem; 2020 Mar; 57(2):106-120. PubMed ID: 31529982
    [No Abstract]   [Full Text] [Related]  

  • 9. Osteoarticular cells tolerate short-term exposure to nitisinone-implications in alkaptonuria.
    Mistry JB; Jackson DJ; Bukhari M; Taylor AM
    Clin Rheumatol; 2016 Feb; 35(2):513-6. PubMed ID: 26024586
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Promising new treatment for type I tyrosinemia.
    Heubi JE
    J Pediatr Gastroenterol Nutr; 1993 Oct; 17(3):340-1. PubMed ID: 8271141
    [No Abstract]   [Full Text] [Related]  

  • 11. New treatment for tyrosinaemia.
    Lancet; 1992 Oct; 340(8823):822-3. PubMed ID: 1357248
    [No Abstract]   [Full Text] [Related]  

  • 12. Patient-reported outcomes and functional assessments of patients with Alkaptonuria in a 3-year Nitisinone treatment trial.
    Spears KR; Rossignol F; Perry MB; Kayser MA; Suwannarat P; O'Brien KE; Bryant JC; Greenwood WF; Fuller S; Gahl WA; Introne WJ
    Mol Genet Metab; 2024; 143(1-2):108562. PubMed ID: 39121793
    [TBL] [Abstract][Full Text] [Related]  

  • 13. NTBC as palliative treatment in chronic tyrosinaemia type I.
    Ros J; Vilaseca MA; Lambruschini N; Mas A; Lindstedt S; Holme E
    J Inherit Metab Dis; 1999 Jun; 22(5):665-6. PubMed ID: 10399099
    [No Abstract]   [Full Text] [Related]  

  • 14. In brief: Nitisinone (Orfadin) for hereditary tyrosinemia.
    Med Lett Drugs Ther; 2016 Oct; 58(1505):e132. PubMed ID: 27701365
    [No Abstract]   [Full Text] [Related]  

  • 15. Inhibition of para-Hydroxyphenylpyruvate Dioxygenase by Analogues of the Herbicide Nitisinone As a Strategy to Decrease Homogentisic Acid Levels, the Causative Agent of Alkaptonuria.
    Laschi M; Bernardini G; Dreassi E; Millucci L; Geminiani M; Braconi D; Marzocchi B; Botta M; Manetti F; Santucci A
    ChemMedChem; 2016 Apr; 11(7):674-8. PubMed ID: 26947423
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Interference of hydroxyphenylpyruvic acid, hydroxyphenyllactic acid and tyrosine on routine serum and urine clinical chemistry assays; implications for biochemical monitoring of patients with alkaptonuria treated with nitisinone.
    Curtis SL; Norman BP; Milan AM; Gallagher JA; Olsson B; Ranganath LR; Roberts NB
    Clin Biochem; 2019 Sep; 71():24-30. PubMed ID: 31228435
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Natural history of alkaptonuria.
    Phornphutkul C; Introne WJ; Perry MB; Bernardini I; Murphey MD; Fitzpatrick DL; Anderson PD; Huizing M; Anikster Y; Gerber LH; Gahl WA
    N Engl J Med; 2002 Dec; 347(26):2111-21. PubMed ID: 12501223
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment of two children with hereditary tyrosinaemia type I and long-standing renal disease with a 4-hydroxyphenylpyruvate dioxygenase inhibitor (NTBC).
    Pronicka E; Rowinska E; Bentkowski Z; Zawadzki J; Holme E; Lindstedt S
    J Inherit Metab Dis; 1996; 19(2):234-8. PubMed ID: 8739974
    [No Abstract]   [Full Text] [Related]  

  • 19. Inhibition of 4-hydroxyphenylpyruvate dioxygenase by 2-(2-nitro-4-trifluoromethylbenzoyl)-cyclohexane-1,3-dione and 2-(2-chloro-4-methanesulfonylbenzoyl)-cyclohexane-1,3-dione.
    Mitchell GA
    Hum Exp Toxicol; 1996 Feb; 15(2):179-81. PubMed ID: 8645506
    [No Abstract]   [Full Text] [Related]  

  • 20. Pregnancy in an NTBC-treated patient with hereditary tyrosinemia type I.
    Kassel R; Sprietsma L; Rudnick DA
    J Pediatr Gastroenterol Nutr; 2015 Jan; 60(1):e5-7. PubMed ID: 23838819
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.